Effect of Two Administration Methods of Endostar Combined with Epirubicin on Breast Cancer in Mice

Objective To compare the effect of endostar via micro pump or intraperitoneal injection combined with epirubicin on breast cancer in mice.

Methods We established the BALB/c mice breast cancer model by orthotopically inoculating 4T1 cells, then they were randomly divided into six groups: blank group(0.9%NaCl, ip), standard control group(EPI, ip) and four experimental groups:(1) rhES(ip)+EPI(ip); (2) rhES(pump)+EPI(ip); (3) rhES(ip); (4) rhES(pump). We monitored tumor xenografts volume, mice weight and drug adverse events every two days until the termination of treatment; We also detected their bioluminescence activity on day 10; after the treatment, mices were sacrificed, tumor xenografts were completely removed and we detected platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) expression level in tumor tissues by IHC.

Results The effect of endostar via micro pump(7 mg/(kg.d)) was better than intraperitoneal injection on breast cancer in mice(P=0.01). The effect of endostar via micro pump combined with epirubicin was equivalent with intraperitoneal injection of two drugs(P > 0.05), and the adverse events in former groups were reduced.

Conclusion The effect of endostar via micro pump combined with epirubicin is equivalent with intraperitoneal injection of two drugs, which provides an experimental basis for the possibility of breast cancer patients carrying endostar micro pump at home, however, more clinical evidence are needed.